MIT’s sponsored research activity is down 10% year-over-year, new federal awards down 20%, and graduate enrollment outside Sloan projected to fall by ~500 students.
Key Takeaways
The 8% endowment tax (raised from 1.4% in the 2025 Big Beautiful Bill) applies only to schools with endowments above $2M per student: MIT, Stanford, Princeton, Yale, Harvard.
Federal funding is not flowing despite Congressional appropriations being partially restored; some agencies are considering geography over scientific merit in allocation.
New graduate enrollments (outside Sloan and EECS MEng) are down close to 20% for next year, a direct result of PIs lacking grant funds to support students.
MIT is pursuing offsets: 176 DOE Genesis Mission proposals submitted, expanded industry partnerships (MIT-IBM Computing Research Lab), new masters-only programs, and a refreshed philanthropy push.
Kornbluth frames this as a mission-level threat, not a trimming exercise: fewer grad students means less basic research and a shrinking pipeline of future scientists.
Hacker News Comment Review
Commenters largely agree the graduate funding mechanism is concrete: PhD admissions at top programs are directly tied to PI grant funding, making enrollment declines an automatic consequence of award declines, not a discretionary choice.
A secondary thread focuses on PhD attrition: roughly 80% of recent PhD grads in some circles are exiting academia, raising questions about whether the pipeline problem is also internal, not just federal policy.
Debate exists on whether budget pressure on universities is net negative; skeptics point to administrative bloat, but replies note the bloat argument conflates undergraduate tuition economics with graduate research funding, which are separate systems.
Notable Comments
@simonw: confirms the 8% endowment tax comes from the 2025 House Ways and Means bill, with the $2M-per-student threshold specifically targeting five schools.
@JumpCrisscross: ties the international student chilling effect directly to brain drain, noting this dynamic previously secured US dominance in research commercialization.
